PMID- 36619341
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2516-5542 (Electronic)
IS  - 2516-5542 (Linking)
VI  - 5
IP  - 2
DP  - 2022 Dec
TI  - Reduced COVID-19 severity elicited by weight loss from a medically supervised 
      ketogenic diet in a geographically diverse ambulatory population with type 2 
      diabetes and obesity.
PG  - 154-158
LID - 10.1136/bmjnph-2022-000444 [doi]
AB  - OBJECTIVE: To investigate factors associated with COVID-19 severity in ambulatory 
      individuals with type 2 diabetes mellitus (T2DM) and obesity treated with a 
      medically supervised ketogenic diet (MSKD). RESEARCH DESIGN AND METHODS: In this 
      real-world, retrospective, exploratory analysis, multivariate modelling was used 
      to assess clinical factors associated with hospitalisation for COVID-19 in a 
      geographically diverse outpatient population with T2DM treated virtually. 
      RESULTS: Leading up to COVID-19 onset, non-hospitalised patients had higher 
      average ketones (0.64 vs 0.52 mmol/L; p=0.016) and greater weight loss (6.8% vs 
      4.2%; p=0.009) compared with those hospitalised. Greater weight loss was 
      significantly associated with lower likelihood of hospitalisation (adjusted 
      OR=0.91, p=0.005), controlling for enrolment demographics and medical 
      characteristics. CONCLUSIONS: Therapies such as MSKD, which elicit rapid, 
      significant weight loss, may favourably impact COVID-19 hospitalisation rate and 
      severity in individuals with T2DM and obesity.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Volk, Brittanie M
AU  - Volk BM
AUID- ORCID: 0000-0003-3530-519X
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
FAU - Roberts, Caroline G P
AU  - Roberts CGP
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
FAU - VanTieghem, Michelle
AU  - VanTieghem M
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
FAU - George, M Patricia
AU  - George MP
AD  - Department of Medicine, National Jewish Health, Denver, Colorado, USA.
FAU - Adams, Rebecca N
AU  - Adams RN
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
FAU - Athinarayanan, Shaminie J
AU  - Athinarayanan SJ
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
FAU - McKenzie, Amy L
AU  - McKenzie AL
AD  - Clinical Research, Virta Health, San Francisco, California, USA.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - England
TA  - BMJ Nutr Prev Health
JT  - BMJ nutrition, prevention & health
JID - 101769223
PMC - PMC9813610
OTO - NOTNLM
OT  - COVID-19
OT  - Diabetes mellitus
OT  - Nutritional treatment
OT  - Weight management
COIS- Competing interests: BMV, CGPR, MVT, RNA, SJA and ALM are employed by Virta 
      Health and offered stock options. MPG served on advisory boards with United 
      Therapeutics, Altavant and Bayer; has been a speaker in pulmonary hypertension 
      for Bayer, Janssen and United Therapeutics; and received grant funding from 
      Janssen.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/10 06:01
PMCR- 2022/07/01
CRDT- 2023/01/09 03:50
PHST- 2022/02/12 00:00 [received]
PHST- 2022/05/20 00:00 [accepted]
PHST- 2023/01/09 03:50 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/10 06:01 [medline]
PHST- 2022/07/01 00:00 [pmc-release]
AID - bmjnph-2022-000444 [pii]
AID - 10.1136/bmjnph-2022-000444 [doi]
PST - epublish
SO  - BMJ Nutr Prev Health. 2022 Jul 1;5(2):154-158. doi: 10.1136/bmjnph-2022-000444. 
      eCollection 2022 Dec.